BidaskClub upgraded shares of GALAPAGOS NV/S (NASDAQ:GLPG) from a sell rating to a hold rating in a research note issued to investors on Friday, October 19th.
Other research analysts have also recently issued reports about the company. Zacks Investment Research cut GALAPAGOS NV/S from a buy rating to a hold rating in a report on Wednesday, July 4th. Credit Suisse Group set a $92.00 price objective on GALAPAGOS NV/S and gave the company a hold rating in a report on Tuesday, August 7th. Stifel Nicolaus cut their target price on GALAPAGOS NV/S from $120.00 to $109.00 and set a buy rating on the stock in a research report on Friday, June 29th. Goldman Sachs Group lowered GALAPAGOS NV/S from a buy rating to a neutral rating in a research report on Thursday, August 9th. Finally, Royal Bank of Canada cut their target price on GALAPAGOS NV/S to $94.00 and set a sector perform rating on the stock in a research report on Friday, June 29th. Four research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. GALAPAGOS NV/S has an average rating of Buy and an average price target of $117.00.
Shares of GALAPAGOS NV/S stock traded down $1.42 on Friday, hitting $105.99. 81,297 shares of the company were exchanged, compared to its average volume of 144,759. GALAPAGOS NV/S has a 1-year low of $84.13 and a 1-year high of $122.28. The stock has a market cap of $5.59 billion, a P/E ratio of -40.15 and a beta of 1.91.
About GALAPAGOS NV/S
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
See Also: Fiduciary
Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.